AZN
AstraZeneca PLC NYSE Listed May 12, 1993$174.93
-1.66%
vs $177.89
Mkt Cap $136.6B
52w Low $137.58
51.9% of range
52w High $209.48
50d MA $187.08
200d MA $181.98
P/E (TTM)
13.4x
EV/EBITDA
7.8x
P/B
2.8x
Debt/Equity
0.6x
ROE
—
P/FCF
11.6x
RSI (14)
37.60
ATR (14)
$3.23
Beta
0.28
50d MA
$187.08
200d MA
$181.98
Avg Volume
1.9M
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
1 Francis Crick Avenue · Cambridge CB2 0AA · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 2.52 | 2.58 | +2.4% | 185.20 | +1.8% | +1.2% | -1.4% | -0.7% | -1.2% | +2.0% | — |
| Feb 10, 2026 | TNS | 2.18 | 2.12 | -2.8% | 193.10 | +3.6% | +6.0% | -0.1% | +0.5% | +1.9% | -0.4% | — |
| Nov 6, 2025 | TNS | 2.29 | 2.38 | +3.9% | 169.00 | +0.3% | -1.7% | +5.3% | +0.2% | +0.3% | +1.0% | — |
| Jul 29, 2025 | TNS | 2.16 | 2.18 | +0.9% | 150.48 | +0.3% | +3.4% | -5.3% | +0.1% | +1.9% | -0.0% | — |
| Apr 29, 2025 | TNS | 2.25 | 2.48 | +10.2% | 144.94 | +1.1% | +0.5% | -3.4% | +4.3% | -0.5% | -4.8% | — |
| Feb 6, 2025 | TNS | 2.07 | 2.10 | +1.4% | 151.50 | -5.3% | -5.7% | +4.4% | -4.7% | +3.1% | +1.7% | — |
| Nov 12, 2024 | TNS | 2.04 | 2.08 | +2.0% | 128.41 | +0.6% | +0.6% | +0.8% | -1.8% | -2.0% | +0.4% | — |
| Jul 25, 2024 | TNS | 1.97 | 1.98 | +0.5% | 155.48 | +1.3% | +2.6% | -2.0% | -0.3% | +2.4% | +0.7% | — |
| Apr 25, 2024 | TNS | 1.91 | 2.06 | +7.9% | 146.05 | +1.6% | -0.7% | +0.8% | +3.2% | +0.0% | +1.6% | — |
| Feb 8, 2024 | TNS | 1.46 | 1.46 | +0.0% | 125.00 | -2.6% | -1.2% | -2.3% | +2.4% | -1.4% | +1.8% | — |
| Nov 9, 2023 | TNS | 0.84 | 1.74 | +106.4% | 126.87 | +0.1% | -2.0% | +0.4% | +0.8% | -0.5% | -0.0% | — |
| Jul 28, 2023 | TNS | 0.99 | 2.16 | +118.6% | 140.84 | -0.6% | +2.8% | -1.4% | -2.6% | -0.1% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13 | UBS | Upgrade | Neutral → Buy | — | $146.43 | $146.50 | +0.0% | +1.7% | -0.2% | -0.5% | -2.1% | +0.4% |
| Nov 20 | UBS | Upgrade | Sell → Neutral | — | $126.02 | $126.58 | +0.4% | -1.0% | +1.1% | +6.2% | -1.8% | -0.1% |
| Sep 11 | Erste Group | Upgrade | Hold → Buy | — | $160.24 | $160.92 | +0.4% | +0.5% | -2.9% | +1.1% | -0.7% | +0.5% |
| Aug 12 | TD Cowen | Maintains | Buy → Buy | — | $162.38 | $160.71 | -1.0% | -1.0% | +1.8% | +1.5% | +0.6% | +1.7% |
| May 30 | Argus | Maintains | Buy → Buy | — | $146.20 | $153.24 | +4.8% | +5.0% | +0.2% | +3.0% | -1.3% | +2.4% |
| Apr 26 | BMO Capital | Maintains | Outperform → Outperform | — | $146.05 | $148.32 | +1.6% | -0.7% | +0.8% | +3.2% | +0.0% | +1.6% |
| Apr 16 | Deutsche Bank | Upgrade | Sell → Hold | — | $135.94 | $138.80 | +2.1% | -0.5% | +3.6% | -1.4% | -1.5% | +1.9% |
| Feb 12 | BMO Capital | Maintains | Outperform → Outperform | — | $123.50 | $122.80 | -0.6% | -2.3% | +2.4% | -1.4% | +1.8% | +2.7% |
| Feb 8 | Deutsche Bank | Downgrade | Buy → Hold | — | $133.34 | $122.00 | -8.5% | -6.3% | -1.2% | -2.3% | +2.4% | -1.4% |
| Jan 3 | Jefferies | Downgrade | Buy → Hold | — | $132.81 | $138.84 | +4.5% | +4.3% | -1.0% | -1.0% | +2.8% | +0.0% |
| Sep 25 | Jefferies | Upgrade | Hold → Buy | — | $137.93 | $131.95 | -4.3% | -0.7% | -1.5% | -1.3% | +2.2% | -0.8% |
| Sep 8 | Erste Group | Downgrade | Buy → Hold | — | $134.68 | $135.84 | +0.9% | +0.8% | -1.8% | -0.7% | -1.6% | +2.2% |
| Aug 1 | BMO Capital | Maintains | Outperform → Outperform | — | $144.82 | $139.00 | -4.0% | -1.4% | -2.6% | -0.1% | +0.9% | +0.7% |
| May 26 | Argus | Maintains | Buy → Buy | — | $145.26 | $144.58 | -0.5% | -0.5% | -2.4% | +3.5% | +1.1% | -0.4% |
| Apr 13 | Argus | Maintains | Buy → Buy | — | $147.25 | $147.25 | +0.0% | +1.6% | -2.4% | +0.5% | +1.4% | -0.7% |
| Nov 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $123.85 | $128.98 | +4.1% | +2.1% | -0.4% | +0.2% | +0.2% | +1.1% |
| Nov 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $127.28 | $129.47 | +1.7% | -2.7% | +2.1% | -0.4% | +0.2% | +0.2% |
| Aug 29 | Argus | Upgrade | Hold → Buy | — | $131.44 | $126.25 | -3.9% | -2.0% | -2.3% | -1.1% | -5.1% | +7.2% |
| May 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $130.08 | $134.32 | +3.3% | -0.6% | -1.3% | -1.6% | -3.3% | +1.9% |
| Feb 24 | SVB Leerink | Maintains | Outperform → Outperform | — | $121.42 | $112.25 | -7.6% | -5.2% | +5.3% | -3.3% | +4.1% | +2.4% |
| Feb 11 | DZ Bank | Upgrade | Sell → Hold | — | $115.75 | $116.82 | +0.9% | -1.4% | -2.4% | +5.2% | +3.2% | +1.3% |
| Dec 7 | Jefferies | Downgrade | Buy → Hold | — | $110.93 | $111.39 | +0.4% | -2.1% | +3.5% | -2.9% | +1.1% | -2.9% |
| Sep 27 | SVB Leerink | Maintains | Outperform → Outperform | — | $122.30 | $118.90 | -2.8% | -4.0% | -0.8% | +2.0% | +2.4% | -3.1% |
| Sep 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $111.92 | $112.00 | +0.1% | +3.0% | +3.4% | -2.0% | +2.0% | +2.6% |
| Aug 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $115.49 | $120.30 | +4.2% | +0.9% | -1.4% | -1.0% | -1.5% | +1.6% |
| Jul 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $116.12 | $115.26 | -0.7% | -0.5% | -3.0% | +3.7% | -1.0% | +1.9% |
| Jun 4 | SVB Leerink | Maintains | Outperform → Outperform | — | $112.00 | $113.75 | +1.6% | +1.7% | -1.2% | +1.1% | +0.2% | +2.6% |
| Apr 12 | Argus | Downgrade | Buy → Hold | — | $101.34 | $99.45 | -1.9% | -2.0% | -0.1% | -0.2% | +3.0% | -1.5% |
| Mar 16 | Jefferies | Upgrade | Hold → Buy | — | $97.00 | $98.05 | +1.1% | +1.6% | +2.1% | -0.2% | -0.8% | +1.9% |
| Mar 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $97.92 | $96.10 | -1.9% | -0.5% | -1.9% | -1.0% | +1.9% | +0.7% |
| Feb 25 | UBS | Upgrade | Neutral → Buy | — | $98.90 | $98.00 | -0.9% | -2.6% | +1.0% | +0.6% | -0.5% | -1.9% |
| Dec 7 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $106.04 | $106.05 | +0.0% | +2.1% | +0.8% | -1.0% | -0.2% | +0.9% |
| May 29 | SVB Leerink | Maintains | Outperform → Outperform | — | $108.00 | $109.30 | +1.2% | -0.7% | +0.7% | +0.7% | -0.1% | +0.5% |
| May 6 | Argus | Maintains | Buy → Buy | — | $106.94 | $110.71 | +3.5% | +3.6% | -6.5% | +3.0% | +1.5% | +0.1% |
| Dec 2 | TD Cowen | Maintains | Outperform → Outperform | — | $97.00 | $97.34 | +0.4% | -0.2% | -2.1% | +1.4% | -0.9% | +0.1% |
| Apr 2 | UBS | Downgrade | Neutral → Sell | — | $80.40 | $81.50 | +1.4% | +0.2% | -0.4% | -0.8% | -0.4% | +3.0% |
| Apr 1 | TD Cowen | Upgrade | Market Perform → Outperform | — | $80.86 | $80.40 | -0.6% | -0.6% | +0.2% | -0.4% | -0.8% | -0.4% |
| Nov 19 | Investec | Downgrade | Buy → Hold | — | $81.34 | $79.53 | -2.2% | -1.3% | +0.5% | -0.3% | -0.1% | -0.3% |
| Aug 16 | Jefferies | Downgrade | Buy → Hold | — | $76.90 | $76.66 | -0.3% | -1.3% | +0.4% | +1.9% | -0.3% | +0.2% |
| May 5 | Argus | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Mar 19 | Jefferies | Upgrade | Hold → Buy | — | $69.18 | $69.66 | +0.7% | -0.1% | +0.6% | +0.6% | -1.5% | -0.9% |
| Feb 6 | Leerink Swann | Maintains | Market Perform → Market Perform | — | $67.80 | $66.70 | -1.6% | +1.2% | -1.2% | +0.6% | -1.4% | +1.4% |
| Dec 29 | JP Morgan | Upgrade | Neutral → Overweight | — | $68.22 | $69.54 | +1.9% | +1.7% | -1.2% | +3.4% | -1.9% | +0.5% |
| Oct 23 | Leerink Swann | Maintains | Market Perform → Market Perform | — | $69.24 | $69.14 | -0.1% | -0.7% | -0.5% | -0.3% | -1.7% | -0.1% |
| Sep 22 | Bernstein | Upgrade | Market Perform → Outperform | — | $64.00 | $67.60 | +5.6% | +6.1% | -2.9% | -1.6% | +2.8% | +0.5% |
| Sep 14 | Liberum | Downgrade | Buy → Hold | — | $65.30 | $65.06 | -0.4% | -0.1% | -0.3% | -3.4% | +4.0% | +0.8% |
| Jul 28 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $58.53 | $59.10 | +1.0% | +1.7% | +1.2% | -0.7% | +0.6% | -1.8% |
| Jul 27 | Leerink Swann | Downgrade | Outperform → Market Perform | — | $67.30 | $57.10 | -15.2% | -13.0% | +1.7% | +1.2% | -0.7% | +0.6% |
| May 15 | Credit Suisse | Upgrade | Underperform → Neutral | — | $66.64 | $67.94 | +2.0% | +2.7% | +0.6% | -2.4% | -0.8% | +1.7% |
| Dec 9 | Leerink Swann | Upgrade | Market Perform → Outperform | — | $52.54 | $53.35 | +1.5% | +3.6% | -1.0% | -0.0% | +1.3% | -1.3% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 45,040,142 | $8.8B | New | Mar 2026 |
| 2 | Fmr Llc | 29,601,724 | $5.8B | New | Mar 2026 |
| 3 | Capital World Investors | 28,264,580 | $5.5B | New | Mar 2026 |
| 4 | Bank Of America Corp /de/ | 19,058,327 | $3.8B | New | Mar 2026 |
| 5 | Vanguard Asset Management, Ltd | 18,535,315 | $3.6B | New | Mar 2026 |
| 6 | Jpmorgan Chase & Co | 18,590,922 | $3.6B | New | Mar 2026 |
| 7 | Primecap Management Co/ca/ | 18,213,708 | $3.6B | New | Mar 2026 |
| 8 | Franklin Resources Inc | 17,792,161 | $3.5B | New | Mar 2026 |
| 9 | Prudential Plc | 165,063 | $3.2B | New | Mar 2026 |
| 10 | Amundi | 15,386,149 | $3.0B | New | Mar 2026 |
| 11 | Janus Henderson Group Plc | 11,949,424 | $2.3B | New | Mar 2026 |
| 12 | Aviva Plc | 11,087,661 | $2.1B | New | Mar 2026 |
| 13 | Royal Bank Of Canada | 10,386,455 | $2.0B | New | Mar 2026 |
| 14 | Royal London Asset Management Ltd | 10,299,563 | $2.0B | New | Mar 2026 |
| 15 | Invesco Ltd. | 10,103,749 | $2.0B | New | Mar 2026 |
| 16 | Bnp Paribas Asset Management Holding S.a. | 7,624,427 | $1.5B | New | Mar 2026 |
| 17 | Causeway Capital Management Llc | 7,421,749 | $1.4B | New | Mar 2026 |
| 18 | Sanders Capital, Llc | 7,065,628 | $1.4B | New | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 6,667,812 | $1.3B | New | Mar 2026 |
| 20 | Nuveen, Llc | 6,779,534 | $1.3B | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$136.62B
Enterprise Value
$155.59B
P/E (TTM)
13.37x
Forward P/E
17.03x
PEG Ratio
0.07x
P/B
2.78x
P/S
2.33x
P/FCF
11.61x
EV/EBITDA
7.85x
Shares Out
781.0M
Financials (TTM)
Revenue
$58.74B
Net Income
$10.26B
EBITDA
$19.83B
Free Cash Flow
$11.77B
Op Cash Flow
$14.57B
EPS Basic
$13.20
EPS Diluted
$13.08
EPS Forward
$10.27
Gross Margin
81.9%
Op Margin
23.4%
Net Margin
17.5%
Balance Sheet
Total Assets
$114.07B
Total Liab.
$65.36B
Total Equity
$48.72B
Cash
$5.74B
LT Debt
$24.71B
Book Value/Sh
$62.86
Debt/Equity
0.61x
Current Ratio
0.94
Quick Ratio
0.72
Returns & Growth
ROE
—
ROA
—
ROIC
13.0%
Rev Growth YoY
+8.6%
EPS Growth YoY
+190.8%
Price Returns
2W
+0.4%
1M
-0.9%
3M
-10.9%
6M
+1.1%
12M
+31.2%
Technicals
52W High
$209.48
52W Low
$137.58
50d MA
$187.08
200d MA
$181.98
RSI (14)
37.60
ATR (14)
$3.23
Beta
0.28
Avg Volume
1.9M
Dividends
Div Rate
$6.56
Div Yield
3.5%
Frequency
2
Ex-Div Date
Feb 20, 2026
Analyst Price Targets
Consensus
$211.00
High
$216.00
Low
$206.00
Median
$211.00
Data updated apr 24, 2026 8:19pm
· Source: financialmodelingprep.com